retatrutide phase 2 trial obesity nejm 2023 Research Guide: What the Data Reported (2026) Retatrutide: Phase 3 Results (Up

That may feel manageable for a few hours, but it often worsens jitters, reflux, nausea, or an underfed feeling later in the day

The relative infant dose (RID), or the maternal weight-adjusted infant dose, was calculated, considering the bioavailability of semaglutide and long-acting dose profiles

The information collected may include technical information such as your IP address, the type of device or browser that you use to access the Services, the operating system on your device, the website or other online service that directed you to our Services, the URLs of the websites you visited before visiting our site, numeric identifiers for your mobile device, identifiers for advertising, identifiers generated from secure hash algorithms, session times and durations, how you use your mouse, keyboard, and other input devices to interact with the Services, and the content that you view on the Services

When to contact your GP or diabetes team : Persistent vomiting preventing fluid intake Severe abdominal pain, especially if radiating to the back (possible pancreatitis) Right upper abdominal pain, fever or jaundice (possible gallbladder problems) Signs of dehydration (dark urine, dizziness, reduced urination) Unexplained hypoglycaemia if on combination therapy New or worsening visual symptoms (especially if you have diabetic retinopathy) Allergic reactions (rash, swelling, breathing difficulties) Most patients tolerate GLP-1 medications well once past the initial adjustment period

Retatrutide is also valuable from an analytical perspective

TRIUMPH-1, the first Phase 3 efficacy readout, was reported on 21 May 2026